New drug combo targets Hard-to-Treat cancers
NCT ID NCT04497116
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkage. The trial is now complete, and results will help guide future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RP-3500 (camonsertib), talazoparib, gemcitabine
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have certain genetic changes.
What could go wrong
This is an early-phase trial focused on safety and dosing, not yet proven to work. The drugs may cause side effects, and the benefit for patients is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
#1001, The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
#1002, Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
#1003, Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
#1004, Memorial Sloan Kettering Cancer Institute
New York, New York, 10065, United States
-
#1005, Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
#1006, Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
#1007, Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
#1014, Northwestern University
Chicago, Illinois, 60611, United States
-
#2001, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
#3001, The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
#3002, Freeman Hospital Newcastle
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
#3003, Sarah Cannon Research Institute
London, W1G 6AD, United Kingdom
-
#4001, Copenhagen University Hospital Rigshospitalet - Blegdamsvej
Copenhagen, DK, 2100 Ø, Denmark